436 related articles for article (PubMed ID: 17378846)
21. Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors.
Taylor J; Baldo OB; Storey A; Cartledge J; Eardley I
BJU Int; 2009 May; 103(10):1392-5. PubMed ID: 19154494
[TBL] [Abstract][Full Text] [Related]
22. Phosphodiesterase type 5 inhibitors' extended duration of response as a variable in the treatment of erectile dysfunction.
Dunn ME; Althof SE; Perelman MA
Int J Impot Res; 2007; 19(2):119-23. PubMed ID: 16738695
[TBL] [Abstract][Full Text] [Related]
23. Use of phosphodiesterase-5 inhibitors by college students.
Freitas VM; Menezes FG; Antonialli MM; Nascimento JW
Rev Saude Publica; 2008 Oct; 42(5):965-7. PubMed ID: 18797570
[TBL] [Abstract][Full Text] [Related]
24. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.
Kloner RA
Am J Cardiol; 2005 Dec; 96(12B):42M-46M. PubMed ID: 16387566
[TBL] [Abstract][Full Text] [Related]
25. [Efficacy and safety of vardenafil in difficult-to-treat erectile dysfunction men].
Wang CH
Zhonghua Nan Ke Xue; 2006 Apr; 12(4):377-80. PubMed ID: 16683577
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic options for patients returning to sexual activity.
Nusbaum MR
J Am Osteopath Assoc; 2004 Mar; 104(3 Suppl 4):S2-5. PubMed ID: 15083992
[TBL] [Abstract][Full Text] [Related]
27. Physician-rated patient preference and patient- and partner-rated preference for tadalafil or sildenafil citrate: results from the Canadian 'Treatment of Erectile Dysfunction' observational study.
Lee J; Pommerville P; Brock G; Gagnon R; Mehta P; Krisdaphongs M; Chan M; Chan J; Dickson R
BJU Int; 2006 Sep; 98(3):623-9. PubMed ID: 16925764
[TBL] [Abstract][Full Text] [Related]
28. [Efficacy and safety of vardenafil for men with erectile dysfunction].
Zhu J; Jiang H
Zhonghua Nan Ke Xue; 2004 Sep; 10(9):704-10. PubMed ID: 15497716
[TBL] [Abstract][Full Text] [Related]
29. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
Ghofrani HA; Voswinckel R; Reichenberger F; Olschewski H; Haredza P; Karadaş B; Schermuly RT; Weissmann N; Seeger W; Grimminger F
J Am Coll Cardiol; 2004 Oct; 44(7):1488-96. PubMed ID: 15464333
[TBL] [Abstract][Full Text] [Related]
30. [Update of PDE5 inhibitors as treatment of ED].
Lu YN; Chen B
Zhonghua Nan Ke Xue; 2005 Jul; 11(7):552-5. PubMed ID: 16078679
[TBL] [Abstract][Full Text] [Related]
31. Vardenafil 20-mg demonstrated superior efficacy to 10-mg in Japanese men with diabetes mellitus suffering from erectile dysfunction.
Ishii N; Nagao K; Fujikawa K; Tachibana T; Iwamoto Y; Kamidono S
Int J Urol; 2006 Aug; 13(8):1066-72. PubMed ID: 16903931
[TBL] [Abstract][Full Text] [Related]
32. Phosphodiesterase type 5 inhibitors: the day after.
Hatzimouratidis K; Hatzichristou D
Eur Urol; 2007 Jan; 51(1):75-88; discussion 89. PubMed ID: 16949200
[TBL] [Abstract][Full Text] [Related]
33. Pharmacology of phosphodiesterase 5 inhibitors.
Carrier S
Can J Urol; 2003 Feb; 10 Suppl 1():12-6. PubMed ID: 12625845
[TBL] [Abstract][Full Text] [Related]
34. A 6 month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Latin American men with erectile dysfunction.
Rubio-Aurioles E; Reyes LA; Borregales L; Cairoli C; Sorsaburu S
Curr Med Res Opin; 2013 Jun; 29(6):695-706. PubMed ID: 23540375
[TBL] [Abstract][Full Text] [Related]
35. [Benefits of tadalafil in sexual activity-related time concerns].
Yuang RQ
Zhonghua Nan Ke Xue; 2010 Jun; 16(6):572-5. PubMed ID: 20608366
[TBL] [Abstract][Full Text] [Related]
36. A 6-month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Middle Eastern and North African men with erectile dysfunction.
El-Meliegy A; Rabah D; Al-Mitwalli K; Mostafa T; Hussein T; Istarabadi M; Lei Y; Gurbuz S
Curr Med Res Opin; 2013 Jun; 29(6):707-17. PubMed ID: 23540436
[TBL] [Abstract][Full Text] [Related]
37. Vardenafil rescue rates of sildenafil nonresponders: objective assessment of 327 patients with erectile dysfunction.
Brisson TE; Broderick GA; Thiel DD; Heckman MG; Pinkstaff DM
Urology; 2006 Aug; 68(2):397-401. PubMed ID: 16904460
[TBL] [Abstract][Full Text] [Related]
38. Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
Mulhall JP; Chopra I; Patel D; Hassan TA; Tang WY
J Sex Med; 2020 May; 17(5):941-948. PubMed ID: 32144034
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors.
Sussman DO
J Am Osteopath Assoc; 2004 Mar; 104(3 Suppl 4):S11-5. PubMed ID: 15083994
[TBL] [Abstract][Full Text] [Related]
40. The COUPLES-project: a pooled analysis of patient and partner treatment satisfaction scale (TSS) outcomes following vardenafil treatment.
Rosen RC; Fisher WA; Beneke M; Homering M; Evers T
BJU Int; 2007 Apr; 99(4):849-59. PubMed ID: 17378845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
